[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"PharmaResearch Co.,Ltd\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":42},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100643032","clinical-trial-to-evaluate-the-efficacy-and-safety-of-conjuran-after-first-and-second-cycle-repeat-administration-in-patients-with-knee-osteoarthritis-100643032",false,"NCT07646483","Clinical Trial to Evaluate the Efficacy and Safety of Conjuran® After First and Second Cycle (Repeat) Administration in Patients With Knee Osteoarthritis","A Multicenter, Randomized, Double-Blind, Active-Controlled, Non-Inferiority Clinical Trial to Evaluate the Efficacy and Safety of Intra-Articular Conjuran® After First and Second Cycle (Repeat) Administration in Patients With Knee Osteoarthritis","Inclusion Criteria:\n\n* Age ≥40 years\n* Knee osteoarthritis diagnosed according to ACR criteria\n* KL grade I-III\n* Weight-bearing pain VAS ≥40 mm\n* Written informed consent\n\nExclusion Criteria:\n\n* Inflammatory or secondary arthritis\n* Recent treatment in the target knee\n* Significant uncontrolled medical conditions\n* Hypersensitivity to study device components\n* Pregnancy or breastfeeding\n* Participation in another clinical trial","ALL","40 Years",{"count":19,"type":20},180,"ESTIMATED","INTERVENTIONAL",[23],"NA","This clinical trial aims to evaluate and compare the efficacy and safety of Conjuran® and Hyruan in patients with knee osteoarthritis following first and second cycle (repeat) administration.",[26],"Knee Osteoarthritis",[28,29],"Polynucleotide sodium","Osteoarthritis","NOT_YET_RECRUITING","2026-06-10",{"date":33,"type":34},"2026-06-12","ACTUAL",{"date":36,"type":20},"2026-06",{"date":38,"type":20},"2028-07",{"name":40,"class":41},"PharmaResearch Co.,Ltd","INDUSTRY",""]